Research in cancer immunology at the Sidney Kimmel Comprehensive Cancer Center (SKCCC), Johns Hopkins University (JHU) has undergone a natural progression from basic laboratory studies of the host immune response to cancer to the clinical evaluation of immune-based cancer therapies. Many of these immune-based strategies to mobilize and augment the anti-tumor immune response were founded on the discoveries made by JHU investigators. Moreover, the application of immunotherapeutic strategies as an adjunct to cancer treatment across a wide range of malignancies and therapeutic settings has expanded dramatically over the past several years. The ability to carefully and reliably quantify the human immune response is critically important to assess the impact of any immunotherapeutic strategy. While there is great diversity in the therapeutic modalities being studied, most areas, in fact, overlap strongly in their techniques and approaches to immunological analysis. Modern immunological techniques for characterizing and quantifying human immune responses are complex, and it is difficult for individual investigators to assemble all the techniques that may be most appropriate for a particular project. The Human Immunology Core Laboratory (HICL) was established in 2005 to provide SKCCC investigators the capacity to reliably monitor and quantify human immune responses using state-of-the-art immunologic assays. Thus, the specific goals of this CORE are to: 1) Provide technical expertise and conduct immunological assays to monitor and characterize the human immune responses;2) Establish standard operating procedures and quality control measures for all immunological assays;3) Communicate its expertise and availability to SKCCC investigators;4) Provide technical support to SKCCC investigators seeking to identify and develop assays specific to their research objectives, and 5) Serve as a repository for key reagents and cell lines useful for the study of human immunology. Taken together, the HICL plays an important role in monitoring human immune responses that crosses many disciplines within the SKCCC and provides for the development of new therapeutic approaches to augment the anti-tumor immune response. Lay: The Human Immunology Core Laboratory identifies different subsets of lymphocytes that participate in the immune response to cancer and assesses their function and their ability to produce inflammatory cytokines that amplify the immune response. By tracking or monitoring the immune response, the Human Immunology Core Laboratory can assist investigators assess the impact or influence of their therapy.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006973-49
Application #
8559547
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-05-07
Project End
2017-04-30
Budget Start
2012-08-09
Budget End
2013-04-30
Support Year
49
Fiscal Year
2012
Total Cost
$73,733
Indirect Cost
$28,219
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Isaacsson Velho, Pedro; Antonarakis, Emmanuel S (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 11:475-486
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Cuviello, Andrea; Goyal, Anshit; Zick, Aviad et al. (2018) Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic BRAF. JCO Precis Oncol 2018:
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663

Showing the most recent 10 out of 2393 publications